During the past decade, Hammersmith Medicines Research conducted 85 clinical trials. In the 10-year time frame, 85 clinical trials started and 12 clinical trials were completed, i.e. on average, 14.1% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 12 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hammersmith Medicines Research" #1 sponsor was "Daiichi Sankyo, Inc." with 8 trials, followed by "Trio Medicines Ltd." with 8 trials sponsored, "Maruho Europe Limited" with 5 trials sponsored, "Poxel SA" with 5 trials sponsored and "Alios Biopharma Inc." with 5 trials sponsored. Other sponsors include 69 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hammersmith Medicines Research" #1 collaborator was "Hammersmith Medicines Research" with 10 trials as a collaborator, "Ferring Pharmaceuticals" with 4 trials as a collaborator, "Bayer" with 3 trials as a collaborator, "Bill and Melinda Gates Foundation" with 3 trials as a collaborator and "Analyst Research Laboratories" with 2 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Hammersmith Medicines Research" are "Healthy" (24 trials), "Healthy Volunteers" (7 trials), "Asthma" (5 trials), "Healthy Volunteer" (4 trials) and "Reflux Oesophagitis" (4 trials). Many other conditions were trialed in "Hammersmith Medicines Research" in a lesser frequency.

Most popular intervention types in "Hammersmith Medicines Research" are "Drug" (99 trials), "Other" (7 trials), "Biological" (6 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (44 trials), "YF476" (7 trials), "placebo" (5 trials), "ASP2151" (4 trials) and "Imeglimin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hammersmith Medicines Research" are 72 trials for "All" genders, 31 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hammersmith Medicines Research". undefined are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 86 completed trials in Hammersmith Medicines Research, 2 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Hammersmith Medicines Research, 98 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".